GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » 3-Year FCF Growth Rate

Samsung BioLogics Co (XKRX:207940) 3-Year FCF Growth Rate : 99.30% (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co 3-Year FCF Growth Rate?

Samsung BioLogics Co's Free Cash Flow per Share for the three months ended in Mar. 2025 was ₩468.85.

During the past 12 months, Samsung BioLogics Co's average Free Cash Flow per Share Growth Rate was -84.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 99.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 11 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Samsung BioLogics Co was 114.30% per year. The lowest was 14.00% per year. And the median was 40.45% per year.


Competitive Comparison of Samsung BioLogics Co's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Samsung BioLogics Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samsung BioLogics Co's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Samsung BioLogics Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Samsung BioLogics Co's 3-Year FCF Growth Rate falls into.


;
;

Samsung BioLogics Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Samsung BioLogics Co  (XKRX:207940) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Samsung BioLogics Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Samsung BioLogics Co Business Description

Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

Samsung BioLogics Co Headlines

No Headlines